This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (31)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Genetic Disorders  • Neurogenetics  • Neuropathology  • Alert me on articles by topic

Neurological Diseases, Neuromodulation, and Drug Development

Edward C. Cooper, MD, PhD; Lily Y. Jan, PhD

Arch Neurol. 2003;60:496-500.

Efforts in basic neuroscience and studies of rare hereditary neurological diseases are partly motivated by the hope that such work can lead to better understanding of and treatments for the common neurological disorders. An example is the progress that has resulted from identification of the genes that cause benign familial neonatal convulsions (BFNCs). Benign familial neonatal convulsions is a rare idiopathic, generalized epilepsy syndrome. In 1998, geneticists discovered that BFNC is caused by mutations in a novel potassium channel subunit, KCNQ2. Further work quickly revealed the sequences of 3 related brain channel genes KCNQ3, KCNQ4, and KCNQ5. Mutations in 2 of these genes were shown to cause BFNC (KCNQ3) and hereditary deafness (KCNQ4). Physiologists soon discovered that the KCNQ genes encoded subunits of the M-channel, a widely expressed potassium channel that mediates effects of modulatory neurotransmitters and controls repetitive neuronal discharges. Finally, pharmacologists discovered that the biological activities of 3 classes of compounds in development as treatments for Alzheimer disease, epilepsy, and stroke were mediated in part by effects on brain KCNQ channels. Cloned human KCNQ channels can now be used for high-throughput screening of additional drug candidates. Ongoing studies in humans and animal models will refine our understanding of KCNQ channel function and may reveal additional targets for therapeutic manipulation.

From the Departments of Neurology (Dr Cooper), Physiology (Drs Cooper and Jan), and Biochemistry (Dr Jan) and the Howard Hughes Medical Institute (Dr Jan), University of California–San Francisco. Dr Cooper is now affiliated with the Department of Neurology, University of Pennsylvania, Philadelphia.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Calmodulin binding to M-type K+ channels assayed by TIRF/FRET in living cells
Bal et al.
J. Physiol. 2008;586:2307-2320.
ABSTRACT | FULL TEXT  

Regulation of neural KCNQ channels: signalling pathways, structural motifs and functional implications
Hernandez et al.
J. Physiol. 2008;586:1811-1821.
ABSTRACT | FULL TEXT  

Inositol Triphosphate-Mediated Ca2+ Signals Direct Purinergic P2Y Receptor Regulation of Neuronal Ion Channels
Zaika et al.
J. Neurosci. 2007;27:8914-8926.
ABSTRACT | FULL TEXT  

Pre- and Postsynaptic Activation of M-Channels By a Novel Opener Dampens Neuronal Firing and Transmitter Release
Peretz et al.
J. Neurophysiol. 2007;97:283-295.
ABSTRACT | FULL TEXT  

Somatodendritic Kv7/KCNQ/M Channels Control Interspike Interval in Hippocampal Interneurons.
Lawrence et al.
J. Neurosci. 2006;26:12325-12338.
ABSTRACT | FULL TEXT  

Opposite regulation of Slick and Slack K+ channels by neuromodulators.
Santi et al.
J. Neurosci. 2006;26:5059-5068.
ABSTRACT | FULL TEXT  

Electrophysiological Properties of Pluripotent Human and Mouse Embryonic Stem Cells
Wang et al.
Stem Cells 2005;23:1526-1534.
ABSTRACT | FULL TEXT  

Meclofenamic Acid and Diclofenac, Novel Templates of KCNQ2/Q3 Potassium Channel Openers, Depress Cortical Neuron Activity and Exhibit Anticonvulsant Properties
Peretz et al.
Mol. Pharmacol. 2005;67:1053-1066.
ABSTRACT | FULL TEXT